• RWE projects focusing on generating evidence using datasets, chart reviews etc.
globally.
• HEOR projects focusing on cost-utility models and adaptations and HEOR strategy and tactics for HTA submissions.
• Evidence strategy and data partner assessmentsfor investments based on capabilities and data asset value.
ViiV (part of GSK)

• Lead development and implementation of Global HTA strategy for lead molecule in HIV for ViiV
• Delivered global core economic and real world evidence
● Core Cost effectiveness, Budget Impact, Cost minimizations models and adaptations to key markets along with HTA strategy e.g. UK, US, Germany, France, China etc.
● Core value messages, GVD and RWE strategy and studies aligned with global access and brand plan.
● Life cycle management e.g. post launch evidence strategy e.g. ITC's, real world studies, paediatric launch etc.
• Cross functional collaborations with global and regional access, medical affairs, regulatory etc.
● Kabra M, Barber T, Allavena C, Marcelin A, Giambenedetto di S, Pasquau J, Gianotti N, Turner M, Harrison C, Wynne T, Verdier G, Parry C, Jones B, Okoli C, Priest J, Letang E. Effectiveness of dolutegravir + lamivudine in real-world studies in people with HIV-1 with M184V/I mutations: a systematic review and meta-analysis. Poster #P081, HIV Glasgow 2022
● Giamb

• HEOR/Health outcomes lead for ViiV portfolio in EU.
• Accountable for developing the European Health Outcomes strategy across the ViiV portfolio, with a focus on leading, managing, and implementing key evidence generation strategies to support ViiV portfolio
• Integration of strategy and health outcomes studies to support ongoing access and pricing negotiations for the ViiV portfolio

 Lead Medical Evidence team, and setting vision for OPEL Evidence strategy and execution, ensuring it is fit for purpose for the Otsuka products across CNS, Oncology and speciality, Nephrology and Digital medicines.
 Leading and developing EG/RWD plans across the portfolio and creating/refining for internal fit-for-purpose EG processes (e.g. NISs, ISSs, RWD, and observational studies, publications / communications).
 Co-leading core activities with global leads for EU e.g. Core CE models, BI, GVD, NMA etc.
 Collaborating closely with key internal stakeholders (i.e. Medical Directors, Market Access , Brand Leads, and Countries) to drive consensus on the need for Evidence activity, and secure funding, and ensuring quality and impactful execution for priority tactics/studies.
 Managed one direct report.
 Publications and posters: o Kabra, M. Margotto, L. Manuguid, F. (2021). Real-world treatment patterns and healthcare resource use in patients with acute myeloid leukemia in Western

• Contract engagements focused on patient centered outcomes and real-world data. Reporting directly to the senior leadership team in these roles. I had dual responsibilities, client engagement, analysis plan development and develop strategic partnerships.
• Develop strategic partnerships with RWD data sources with an objective to provide clinical/claims RWD+ patient RWD to industry. Explore partnerships with organisations/groups (including regulators and payors) to enrich patient centric RWD. Project management, strategic oversight and support on Market Access and HEOR projects.

• Lead on delivery of Real world data programmes on HEOR and Market access objectives e.g. health resource utilizations, treatment patterns, switching etc.
• Client engagement, project ideation, scoping for RWD engagements for in-house and database projects, analysis plan review, project management.
• Core team who developed PGRx /ANSER RWD datasets worth more than $1.5mn per year
• Lead projects to develop value messages, product positioning in haematology, CV, CNS etc. supported via expert clinician interviews.
• Project management and matrix leadership to achieve project milestones for CE,BI modelling projects.

• Lead conversations with clients to identify and support commercial evaluation of products for licensing opportunities based on primary research data.
• Work along with healthcare research and consulting teams to prepare commercially viable & customized content-sets for clients upon understanding their key objectives. Negotiating for bespoke projects and consultancy. Managing the complete contract discussion, negotiation and prices collaborating with finance, legal and R&A.
• Consult on product enhancement based on current market gaps.
• Reporting and presenting to Managing Director quarterly forecasts and plans and strategy to drive sales and brand awareness.

• Client engagement on projects focussing on Market assessment, sizing, evaluation of competitive landscape, licensing opportunities valuation, funding etc.
• Represented Datamonitor in CPHi, BIO Europe, 2010

Contract
position focused on genotyping of the mouse Knockout/Knock in samples so as track the genetic changes for model generation. Genotyping was done using PCR amplification and gel detection, Amplifluor using ABIPrism, TAQMAN, MAB-Marker Assisted Backcross.